

# NCPE Assessment

## Plain English Summary

March, 2026

**Drug name:**

Sotatercept (pronounced Soe-TAT-er-sept) for the treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO Functional Class (FC) II to III, to improve exercise capacity

**Brand name:**

Winrevair®

**HTA ID:**

24041

## What is the NCPE?

---

The National Centre for Pharmacoeconomics (NCPE) is a team of experts who look at the health benefits and costs of medicines. The HSE asks us to advise on whether or not a new medicine is good value for money. We give unbiased advice to help the HSE provide the most effective, safe and cost-effective (value for money) treatments for patients.

## How do we make our recommendations?

---

Our main focus is on the health benefits and cost effectiveness of a medicine. We look at the wider costs and health benefits associated with a new medicine, for example:

- Does the new medicine work better than other treatments available in Ireland?
- Is the new medicine easier to give or easier to take compared with other treatments available in Ireland?
- Does the new medicine reduce the need for patients to be hospitalised?
- Does the new medicine improve the quality of a patient's life over other treatments available in Ireland?
- Will the new medicine save resources elsewhere within the health system?

We review the information from clinical trials along with the cost and value for money data presented by the pharmaceutical company. We ask doctors and other healthcare professionals for advice about any health benefits of the new medicine compared with current treatments. We also ask patient organisations to send us their views on how the new drug may improve patients' day-to-day experience of living with a disease.

## What is sotatercept used for?

---

Sotatercept can be used to treat adults with pulmonary arterial hypertension (PAH). Patients with PAH have an abnormally high blood pressure in the arteries of the lungs, causing symptoms such as breathlessness and fatigue. It is used in combination with other PAH medicines in patients with moderate or marked limitations of physical activity (corresponding to WHO functional class II or III respectively).

## What recommendation has the NCPE made to the HSE?

We have recommended that the HSE should not consider sotatercept (when given in combination with background therapies) for this indication. The HSE will consider our recommendation and make the final decision about reimbursement (funding). When making the funding decision, the HSE will also consider the additional [criteria](#) outlined in the Health (Pricing and Supply of Medical Goods) Act 2013.

## Why did we make this recommendation?

---

After reviewing the data presented by the pharmaceutical company, we believe there is some evidence that sotatercept may work as well or better than other medicines at improving exercise capacity, however there is limited evidence that this will translate to impacts on long-term benefits including on the quality and length of life of a person living with PAH. We believe that the price of sotatercept is too high compared with other ways to manage this condition, and we have concluded that the medicine is poor value for money.

## Next steps

---

When the HSE receives our recommendation, it will look at all the relevant data about sotatercept. The HSE makes the final decision on reimbursement.

## Where can I get more information?

---

You can get more information about sotatercept from the following online options:

- the NCPE Technical Summary Document
- Winrevair® European Public Assessment Report (EPAR) – [Medicine Overview](#), or
- searching for sotatercept on our website ([www.ncpe.ie](http://www.ncpe.ie));
- searching for sotatercept on the European Medicines Agency (EMA) website ([www.ema.europa.eu](http://www.ema.europa.eu)).

Please refer to the NCPE website for updated information on the reimbursement status of this medicine